Smart dosing of immunotherapy combo shows promise for kidney cancer
NCT ID NCT06860386
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests whether adjusting doses of two drugs—pembrolizumab (Keytruda) and axitinib (Inlyta)—based on tumor response can better control advanced kidney cancer. The study aims to enroll 75 adults with clear cell renal cell carcinoma that has spread. The trial is currently suspended.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pembrolizumab (Keytruda) and axitinib (Inlyta)
- What this could lead to
- If successful, this could show that adjusting drug doses based on tumor response helps control advanced kidney cancer longer with fewer side effects.
- What could go wrong
- This is a small, early-phase trial that is currently suspended. The adaptive dosing approach may not improve outcomes, and side effects from the drugs can be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we predict who needs extra therapy after kidney cancer surgery?
- Can a pill rewrite the genetic story of resistant kidney cancer?
- Can a Two-Pronged immune attack shrink kidney tumors before surgery?
- Can a Two-Drug combo outsmart advanced cancers?
- Can a rapid drug switch outsmart advanced kidney cancer?
- Can a new nucleotide analogue boost cancer treatment?